Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Witty's Successor: The Shortlist

This article was originally published in Scrip

Executive Summary

"The board will now start a formal search for a successor and will consider internal and external candidates for the role," said GlaxoSmithKline PLC's chair Sir Philip Hampton, and the games begin.

You may also be interested in...



GSK Management Shake Up Ahead Of New CEO Sees Hussain Out, AZ's Miels In

"Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company," stated GSK's out-going CEO Andrew Witty, as Abbas Hussain decides to leave the company having lost out on the top job, which went to Emma Walmsley. His successor will be AstraZeneca's Luke Miels.

Will GSK’s Walmsley Be Feared As ‘Witty But Worse’?

The announcement that Emma Walmsley is to take over from Sir Andrew Witty as CEO of GSK is surprising in more ways than one.

GSK’s New CEO Designate Walmsley Fortifies Volume Growth Strategy

GSK’s new CEO will be Emma Walmsley, currently head of its Consumer Healthcare division. While some investors had wished for a company outsider with a ‘fresh pair of eyes’, GSK’s board decided to go for the best of both worlds: an insider with plenty of non-pharma experience.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC064770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel